SOBI have specialised in the treatment of rare disease since the company was formed by the merger of Swedish Orphan and Biovitrum in 2010. Our focus includes development of our own products as well as working with leading global partner companies.

Our current principal areas are rheumatoid/inflammatory disease and inherited and metabolic disorders. Our expertise lies in our skill in working with specialised conditions and rare diseases. 

We actively seek new products to improve our ability to meet the evolving needs of people with rare diseases.